

内科学第二

論文

A 欧文

A-a

- 1 . Okuno D, Kido T, Muramatsu K, Tokutsu K, Moriyama S, Miyamura T, Hara A, Ishimoto H, Yamaguchi H, Miyazaki T, Sakamoto N, Obase Y, Ishimatsu Y, Fujino Y, Yatera K, Matsuda S, Mukae H: Impact of Corticosteroid Administration within 7 Days of the Hospitalization for Influenza Pneumonia with Respiratory Failure: A Propensity Score Analysis Using a Nationwide Administrative Database. *J Clin Med* 10(3): 494, 2021. (IF: 3.303) *
- 2 . Yanagihara K, Kosai K, Mikamo H, Mukae H, Takesue Y, Abe M, Taniguchi K, Petigara T, Kaku M: Serotype distribution and antimicrobial susceptibility of *Streptococcus pneumoniae* associated with invasive pneumococcal disease among adults in Japan. *Int J Infect Dis* 102(1): 260-268, 2021. (IF: 3.623) *
- 3 . Hirayama T, Miyazaki T, Sumiyoshi M, Ashizawa N, Takazono T, Yamamoto K, Imamura Y, Izumikawa K, Yanagihara K, Kohno S, Mukae H: ERG3-encoding sterol C5,6-DESATURASE in *Candida albicans* is required for virulence in an enterically infected invasive candidiasis mouse model. *Pathogens* 10(1): 23, 2021. (IF: 3.492) *★
- 4 . Iriki J, Yamamoto K, Senju H, Nagaoka A, Yoshida M, Iwasaki K, Ashizawa N, Hirayama T, Tashiro M, Takazono T, Imamura K, Miyazaki T, Izumikawa K, Yanagihara K, Tsujino A, Fukuoka J, Uetani M, Satoh M, Mukae H: Influenza A (H3N2) infection followed by anti-signal recognition particle antibody-positive necrotizing myopathy: A case report. *Int J Infect Dis* 103(2): 33-36, 2021. (IF: 3.623) *
- 5 . Sakamoto S, Kataoka K, Kondo Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saitoh T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S: Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan: Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized trial. *Eur Respir J* 57(1), 2000348, 2021. (IF: 16.671) *
- 6 . Ubukata K, Wajima T, Takata M, Murayama SY, Morozumi M, Mukae H, Ishida T, Miyairi I, Kiyota H, Iwata S: Molecular epidemiological characterization in mucoid-type *Streptococcus pneumoniae* isolates obtained from invasive pneumococcal disease patients in Japan. *J Infect Chemother* 27(2): 211-217, 2021. (IF: 2.211) *
- 7 . Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A, Okamoto M, Endo Y, Tsuji S, Takatani A, Umeda M, Fukui S, Sumiyoshi R, Kawashiri S, Iwamoto N, Igawa T, Ichinose K, Tamai M, Sakamoto N, Nakamura H, Origuchi T, Mukae H, Kuwana M, Kawakami A: IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. *J Intern Med* 289(2): 206-220, 2021. (IF: 8.989) *
- 8 . Dotsu Y, Fukuda M, Honda N, Gyotoku H, Kohno Y, Suyama T, Umeyama Y, Taniguchi H, Takemoto S, Yamaguchi H, Miyazaki T, Sakamoto N, Obase Y, Ikeda H, Ashizawa K, Mukae H: Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. *Thorac Cancer* 12(2): 272-276, 2021. (IF: 3.500) *
- 9 . Kamada M, Shimamoto A, Mori M, Tsutsui S, Zaizen Y, Fukuda M, Matsumoto K, Nagayasu T, Ashizawa K: Tracheal paraganglioma: a case report and review of the pertinent literature. *Intern Med*, 60(14): 2275-2283, 2021. (IF: 1.271) *
- 10 . Taniguchi H, Takemoto S, Ozasa M, Honda N, Suyama N, Umeyama Y, Dotsu Y, Nakao T, Kojima T, Gyotoku H, Yamaguchi H, Miyazaki T, Sakamoto N, Obase Y, Fukuda M, Fukuoka J, Mukae H: Remarkable response to pembrolizumab with platinum-doublet in PD-L1-low pulmonary sarcomatoid carcinoma with few immune cell infiltration: a case report. *Thorac Cancer* 12(7): 1126-1130, 2021. (IF: 3.500) *
- 11 . Tahara M, Fujino Y, Yamasaki K, Oda K, Kido T, Sakamoto N, Kawanami T, Kataoka K, Egashira R, Hashisako M, Suzuki Y, Fujisawa T, Mukae H, Suda T, Yatera K: Exposure to PM(2.5) is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a case-control study. *Respir Res* 22(1): 80, 2021. (IF: 3.920) *
- 12 . Takazono T, Ito Y, Tashiro M, Nakano Y, Hirayama T, Hosogaya N, Saijo T, Yamamoto K, Imamura Y, Miyazaki T, Yanagihara K, Kohno S, Mukae H, Izumikawa K: Transition of triazole-resistant *Aspergillus fumigatus* isolates in a Japanese tertiary hospital and subsequent genetic analysis. *J Infect Chemother* 27(3): 537-539, 2021. (IF: 2.211) *
- 13 . Okuno D, Oshima K, Miyazaki T, Ashizawa N, Hirayama T, Takazono T, Sijo T, Yamamoto K, Imamura Y, Yamaguchi H, Sakamoto N, Obase Y, Izumikawa K, Yanagihara K, Mukae H: Duration of antifungal therapy for septic pulmonary embolism caused by *Candida albicans* from a central venous catheter: A case report. *Clin Case Rep* 9(2): 707-710, 2021. (IF: 0.200) *
- 14 . Muta K, Kitamura M, Hidaka M, Ota Y, Hatra T, Soyama A, Miura S, Miyazaki H, Nakao K, Eguchi S, Mukae H, Nishino T: Association Between Trough Level of Tacrolimus and Change in Estimated Glomerular Filtration Rate 1 Year After Living Donor Liver Transplantation. *Ann Transplant* 26: e928858, 2021. *
- 15 . Hosogaya N, Takazono T, Yokomatsu A, Hiroi S, Ikeoka H, Iwasaki K, Takeshima T, Mukae H: Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis. *J Med Econ* 24(1): 244-254, 2021. (IF: 2.448) *
- 16 . Akagi K, Matsutake T, Fukushima K, Mukae H, Kurohama H, Matsumoto H: A refractory pleural effusion caused by a pleural capillary hemangioma. *Respir Med Case Rep* 23: 101384, 2021. (IF: 0.280)
- 17 . Ashizawa N, Takazono T, Ohyama K, Nagasaki Y, Okamoto M, Hirayama T, Takahashi K, Yamanashi H, Tashiro M, Hosogaya N, Tanaka T, Yamamoto K, Fukuda Y, Imamura Y, Kawanami T, Miyazaki T, Sawai T, Fukushima K, Yatera K, Yanagihara K, Izumikawa K, Mukae H: Evaluation of four commercial severe acute respiratory coronavirus 2 antibody tests. *J Infect Chemother* 27(7): 1033-1038, 2021. (IF: 2.211) *
- 18 . Nabeshima T, Takazono T, Ashizawa N, Miyazaki T, Inoue S, Ngwe Tun MM, Izumikawa K, Mukae H, Moi ML, Morita K: COVID-19 cryptic transmission and genetic information blackouts: Need for effective surveillance policy to better understand disease burden. *Lancet Reg Health West Pac* 7: 100104, 2021.
- 19 . Han K, Blair RV, Iwanaga N, Liu F, Russell-Lodrigue KE, Qin Z, Midkiff CC, Golden NA, Doyle-Meyers LA, Kabir ME, Chandler KE, Cutrera KL, Ren M, Monjure CJ, Lehmicke G, Fischer T, Beddingfield B, Wanek AG, Birnbaum A, Maness NJ, Roy CJ, Datta PK, Rappaport J, Kolis JK, Qin X: Lung expression of human angiotensin-converting enzyme 2 sensitizes the mouse to SARS-CoV-2 infection. *Am J Respir Cell Mol Biol*. 64(1): 79-88, 2021. (IF: 7.748) *

- 20 . Beddingfield BJ, Iwanaga N, Chapagain PP, Zheng W, Roy CJ, Hu TY, Kolls JK, Bix GJ: The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. *JACC Basic Transl Sci.* 6(1): 1-8, 2021. (IF: 9.531) *
- 21 . Irifune S, Yamamoto K, Ishijima S, Koike Y, Fukuoka J, Mukae H: Erythema induratum of Bazin – a subcutaneous granulomatous vasculitis caused difficulty in walking. *Int J Infect Dis* 106(5): 183-184, 2021. (IF: 3.623) *
- 22 . Torigoe K, Muta K, Tsuji K, Yamashita A, Abe S, Ota Y, Mukae H, Nishino T: Safety of renal biopsy by physicians with short nephrology experience. *Healthcare* 9(4): 474, 2021. (IF: 2.645) *
- 23 . Hosogaya N, Miyazaki T, Fukushima Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Kurokawa T, Kawasaki Y, Hanawa M, Fujii Y, Hanaoka H, Iwani S, Watashi K, Yamagoe S, Miyazaki Y, Wakita T, Izumikawa K, Yanagihara K, Mukae H, Kohno S: Nelfinavir Study Group: Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial. *Trials*: 22(1): 309, 2021. (IF: 2.279) *
- 24 . Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N, Sato T, Kanda E, Fukuda M, Oga T, Noda K, Oka M: A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. *Clin Chim Acta* 519: 51-59, 2021. (IF: 3.786) *
- 25 . Takazono T, Yamamoto K, Okamoto R, Morimoto S, Izumikawa K, Mukae H: Effect of surgical masks on droplet dispersion under various oxygen delivery modalities. *Crit Care* 25: 89, 2021. (IF: 9.097) *
- 26 . Okuno D, Sakamoto N, Tagod MSO, Akiyama Y, Moriyama S, Miyamura T, Hara A, Kido T, Ishimoto H, Ishimatsu Y, Tanaka T, Ishihara J, Takeda K, Tanaka Y, Mukae H: Screening of inhibitors targeting heat shock protein 47 involved in the development of idiopathic pulmonary fibrosis. *ChemMedChem* 16(16): 2515-2523, 2021. (IF: 3.124) *
- 27 . Sakamoto N, Hamada N, Okamoto M, Tobino K, Ichiyasu H, Ishii H, Ichikado K, Morimoto S, Hosogaya N, Mukae H: Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study. *BMJ Open* 11(6): e047249, 2021. (IF: 2.692) *
- 28 . Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N, Nishiyama A, Yatera K, Kuyama S, Fukuda M, Ushijima S, Umeguchi H, Harada D, Kashiwabara K, Suetsugu T, Fujimoto N, Tanaka F, Uramoto H, Yoshii C, Nakatomi K, Koh G, Seki N, Aoe K, Nosaki K, Inoue K, Takamori A, Kawaguchi A: The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. *Cancer Med* 10(12): 3873-3885, 2021. (IF: 4.452) *
- 29 . Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, Chibana K, Inoue K, Miura S, Tanaka K, Ebi N, Suetsugu T, Harada T, Kirita K, Yokoyama T, Nakatani Y, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K: A phase II study of osimertinib for radiotherapy-naïve CNS metastasis from non-small cell lung cancer: Results for the T790M cohort of the OCEAN study (LOGIK1603/WJOG9116L). *J Thorac Oncol* 16(12): 2121-2132, 2021. (IF: 15.609) *
- 30 . Irifune S, Ashizawa N, Takazono T, Mutantu P, Nabeshima T, Ngwe Tun MM, Ota K, Hirayama T, Fujita A, Tashiro M, Tanaka T, Yamamoto K, Imamura Y, Miyazaki T, Sawai T, Izumikawa K, Yanagihara K, Morita K, Mukae H: Discrepancy of SARS-CoV-2 PCR results due to the sample collection sites and possible improper sampling. *J Infect Chemother* 27(10): 1525-1528, 2021. (IF: 2.211) *
- 31 . Ozasa M, Zaizen Y, Tabata K, Kataoka K, Sato S, Bychkov A, Sakamoto N, Mukae H, Kondoh Y, Fukuoka J: Recognition of Connective Tissue disease-related interstitial pneumonia based on histological score-a validation study of an online diagnostic decision support tool. *Diagnostics* 11(8): 1359, 2021. (IF: 3.706) *
- 32 . Ishida T, Seki M, Oishi K, Tateda K, Fujita J, Kadota JI, Kawana A, Izumikawa K, Kikuchi T, Ohmagari N, Yamada M, Maruyama T, Takazono T, Miki M, Miyazaki Y, Yamazaki Y, Kakeya H, Ogawa K, Nagai H, Watanabe A: Clinical manifestations of adult patients requiring influenza-associated hospitalization: A prospective multicenter cohort study in Japan via internet surveillance. *J Infect Chemother* 27(3): 480-485, 2021. (IF: 2.211) *
- 33 . Ota Y, Obata Y, Takazono T, Tashiro M, Wakamura T, Takahashi A, Shiozawa Y, Miyazaki T, Nishino T, Izumikawa K: Association between potassium supplementation and the occurrence of acute kidney injury in patients with hypokalemia administered liposomal amphotericin B: a nationwide observational study. *BMC Nephrol* 22(1): 240, 2021. (IF: 2.388) *
- 34 . Obata Y, Takazono T, Tashiro M, Ota Y, Wakamura T, Takahashi A, et al. The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study. *Clin Exp Nephrol* 25(3): 279-87, 2021. (IF: 2.801) *
- 35 . Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, Ajisawa Y, Iwata S, Watanabe H, Honda K, Kitanishi Y, Hara K, Mukae H: Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study. *Clin Infect Dis* 72(11): e859-867, 2021. (IF: 9.079) *
- 36 . Ito Y, Takazono T, Koga S, Nakano Y, Ashizawa N, Hirayama T, Tashiro M, Saijo T, Yamamoto K, Imamura Y, Miyazaki T, Yanagihara K, Izumikawa K, Mukae H: Clinical and experimental phenotype of azole-resistant *Aspergillus fumigatus* with a HapE splice site mutation: a case report. *BMC Infect Dis* 21(1): 573, 2021. (IF: 3.090) *
- 37 . Ideguchi S, Yamamoto K, Tahara M, Koga T, Ide S, Hirayama T, Takazono T, Imamura Y, Miyazaki T, Sakamoto N, Morimoto S, Izumikawa K, Yanagihara K, Ashizawa K, Aoki T, Kawakami A, Yatera K, Mukae H: Infectious pneumonia and lower airway microorganisms in patients with rheumatoid arthritis. *J Clin Med* 10(16): 3552, 2021. (IF: 4.964) *
- 38 . Ideguchi S, Yamamoto K, Hirayama T, Takazono T, Imamura Y, Miyazaki T, Sakamoto N, Izumikawa K, Yanagihara K, Morimoto S, Mukae H: Diagnostic evaluation of serum (1,3)- β -D-glucan levels using the Fungitec G-Test MK kit for *Pneumocystis jirovecii* pneumonia (PCP) in non-HIV patients. *Med Mycol* 59(6): 616-623, 2021. (IF: 4.076) *○
- 39 . Qin Z, Liu F, Blair R, Wang C, Yang H, Mudd J, Currey JM, Iwanaga N, He J, Mi R, Han K, Midkiff CC, Alam MA, Aktas BH, Heide RSV, Veazey R, Piedimonte G, Maness NJ, Ergün S, Mauvais-Jarvis F, Rappaport J, Kolls JK, Qin X: Endothelial cell infection and dysfunction, immune activation in severe COVID-19. *Theranostics* 11(16): 8076-8091, 2021. (IF: 11.600) *
- 40 . Dotsu Y, Yamaguchi H, Fukuda M, Suyama T, Honda N, Umeiyama Y, Taniguchi H, Gytoku H, Takemoto S, Tagawa R, Ogata R, Tomono H, Shimada M, Senju H, Nakatomi K, Nagashima S, Soda H, Ikeda H, Ashizawa K, Mukae H: Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor. *J Clin Med.* 10(18): 4221, 2021. (IF: 4.241) *

- 41 . Yamamoto K, Hosogaya N, Sakamoto N, Yoshida H, Ishii H, Yatera K, Izumikawa K, Yanagihara K, Mukae H: Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration; protocol for an exploratory, multicenter, open-label, randomized-controlled trial (CAME COVID study). *BMJ Open* 11(9): e053325, 2021. (IF: 3.006) *
- 42 . Komeda T, Takazono T, Hosogaya N, Ogura E, Miyauchi H, Iwata S, Mukae H: Reply to Shirata et al. *Clin Infect Dis* 73(7): e1766-e1767, 2021. (IF: 9.079) *
- 43 . Komeda T, Takazono T, Hosogaya N, Miyazaki T, Ogura E, Iwata S, Miyauchi H, Honda K, Fujiwara M, Ajisawa Y, Watanabe H, Kitanishi Y, Hara K, Mukae H: Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study. *Clin Infect Dis* 73(5): e1181-e1190, 2021. (IF: 9.079) *
- 44 . Takazono T, Mukae H, Izumikawa K, Hasegawa N, Yokoyama A: COVID-19 associated pulmonary aspergillosis: a nationwide survey by the Japanese Respiratory Society. *ERJ Open Res* 7(4): 00402-2021, 2021. *
- 45 . Hayashi K, Kitamura M, Tomura H, Yamaguchi K, Kawazu T, Sawase K, Harada T, Ichikawa T, Takazono T, Funakoshi S, Mukae H, Nishino T. Hemodialysis Patient with Diffuse Liver Calcification After Septic Shock. *Am J Case Rep.* 28; 22: e933386. 2021. (IF: 0.250) *
- 46 . Fukushima K, Kubo T, Akagi K, Miyashita R, Kondo A, Ehara N, Takazono T, Sakamoto N, Mukae H: Clinical evaluation of QuantiFERON®-TB Gold Plus directly compared with QuantiFERON®-TB Gold In-Tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly. *J Infect Chemother.* 27(12):1716-1722, 2021. (IF: 2.211) *
- 47 . Tashiro M, Takazono T, Ota Y, Wakamura T, Takahashi A, Sato K, Miyazaki T, Obata Y, Nishino T, Izumikawa K: Efficacy of early administration of liposomal amphotericin B in patients with septic shock: A nationwide observational study. *J Infect Chemother* 27(10): 1471-1476, 2021. (IF: 2.211) *
- 48 . Ishimoto H, Sakamoto N, Ozasa M, Tsutsui S, Hara A, Kido T, Yamaguchi H, Yamamoto K, Obase Y, Ishimatsu Y, Mukae H: Idiopathic desquamative interstitial pneumonia diagnosed using transbronchial lung cryobiopsy: A case report. *Respir Med Case Rep* 34:101523, 2021. (IF: 0.820) *
- 49 . Sakamoto N, Ishimoto H, Tahara M, Kido T, Hara A, Miyamura T, Okuno D, Tokito T, Yoshioka S, Morimoto S, Takazono T, Yamamoto K, Yamaguchi H, Obase Y, Ishimatsu Y, Yatera K, Mukae H: HLA-B*54 is an independent risk factor for pneumonia in Japanese patients with interstitial lung disease: A multicenter retrospective cohort study. *Respir Med* 188: 106612, 2021. (IF: 3.415) *
- 50 . Mutantu PN, Ngwe Tun MM, Nabeshima T, Yu F, Mukadi PK, Tanaka T, Tashiro M, Fujita A, Kanie N, Oshiro R, Takazono T, Imamura Y, Hirayama T, Moi ML, Inoue S, Izumikawa K, Yasuda J, Morita K: Development and evaluation of quantitative immunoglobulin G enzyme-linked immunosorbent assay for the diagnosis of coronavirus disease 2019 using truncated recombinant nucleocapsid protein as assay antigen. *Int J Environ Res Public Health* 18(18): 9630, 2021. (IF: 3.364)
- 51 . Iwanaga N, Chen K, Yang H, Lu S, Hoffmann JP, Wanek A, McCombs JE, Song K, Rangel-Moreno J, Norton EB, Kolls JK: Vaccine-driven lung TRM cells provide immunity against *Klebsiella* via fibroblast IL-17R signaling. *Sci Immunol* 6(63): eabf1198, 2021. (IF: 30.663) *
- 52 . Ishimoto H, Sakamoto N, Oriyama S, Urata M, Nakada N, Hara A, Kido T, Yamaguchi H, Yamamoto K, Obase Y, Ishimatsu Y, Mukae H: Removal of an aspirated tooth from the bronchus using a cryoprobe: A case report. *Respirol Case Rep* 9(12): e0880, 2021. (IF: 0.240)
- 53 . Fukuda K, Yamasaki K, Ogura Y, Kawanami T, Ikegami H, Noguchi S, Akata K, Katsura K, Yatera K, Mukae H, Hayashi T, Taniguchi H: A human respiratory tract-associated bacterium with an extremely small genome. *Commun Biol* 4(1): 628, 2021.
- 54 . Iwanaga Y, Kawanami T, Yamasaki K, Sakakibara H, Ikushima I, Ikegami H, Tahara M, Akata K, Mukae H, Yatera K: A fatal case of COVID-19-associated invasive pulmonary aspergillosis. *J Infect Chemother* 27(7): 1102-1107, 2021. (IF: 2.211) *
- 55 . Ota K, Yanagihara K, Sasaki D, Kaku N, Uno N, Sakamoto K, Kosai K, Miyazaki T, Hasegawa H, Fujita A, Tashiro M, Tanaka T, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S: Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal samples. *PLoS One* 16(6): e0252964, 2021. (IF: 3.240) *
- 56 . Torigoe K, Muta K, Tsuji K, Yamashita A, Torigoe M, Abe S, Ota Y, Mukae H, Nishino T: Association of Urinary Dickkopf-3 with Residual Renal Function Decline in Patients Undergoing Peritoneal Dialysis. *Medicina* 57(6): 631, 2021.
- 57 . Kaku N, Ota K, Sasaki D, Akamatsu N, Uno N, Sakamoto K, Kosai K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K: Had COVID-19 spread in the community before the first confirmed case in Nagasaki, Japan? *Microbes Infect* 23(4-5): 104812, 2021. (IF: 2.700) *
- 58 . Kaku N, Hashiguchi K, Akamatsu N, Wakigawa F, Matsuda J, Komaru K, Nakao T, Harada T, Hara A, Uno N, Sakamoto K, Morinaga Y, Kitazaki T, Hasegawa H, Miyazaki T, Fukuda M, Izumikawa K, Mukae H, Yanagihara K: Evaluation of a novel rapid TRC assay for the detection of influenza using nasopharyngeal swabs and gargle samples. *Eur J Clin Microbiol Infect Dis* 40(8): 1743-1748, 2021. (IF: 3.267)
- 59 . Noguchi S, Yatera K, Kawanami T, Ikegami H, Hata R, Yamasaki K, Fukuda K, Mukae H: Association of obligate anaerobes in bacterial pleurisy caused by *Streptococcus anginosus* group. *Respir Investig* 59(5): 686-690, 2021. (IF: 0.570)
- 60 . Takemoto S, Akagi K, Ono S, Tomono H, Honda N, Suyama T, Umeyama Y, Dotsu Y, Taniguchi H, Ogawara D, Senju H, Gyotoku H, Sugasaki N, Yamaguchi H, Nakatomi K, Fukuda M, Mukae H: Efficacy of S-1 after pemetrexed in patients with non-small cell lung cancer: a retrospective multi-institutional analysis. *Thorac cancer* 12(17): 2289-2423, 2021. (IF: 3.500) *
- 61 . Tsuchiya T, Matsumoto K, Miyazaki T, Doi R, Tokunaga S, Yamaguchi H, Tomoshige K, Watanabe H, Nagayasu T, Sugio K: A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study. *BMC Cancer* 21(1): 249-254, 2021. (IF: 4.430) *
- 62 . Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K: Impact of cancer cachexia on the therapeutic outcome of combined chemioimmunotherapy in patients with non-small cell lung cancer: a retrospective study. *Oncoimmunology* 10(1): e1950411-9, 2021. (IF: 8.110) *

- 63 . Morimoto K, Yamada T, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Takayama K: Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. *Lung Cancer* 161: 26-33, 2021. (IF: 5.705) *
- 64 . Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, Takeshita M, Chihara Y, Yamada T, Hiranuma O, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K: Early discontinuation of induction therapy in chemioimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. *J Cancer Res Clin Oncol* 148(9): 2437-2446, 2021. (IF: 4.553) *
- 65 . Kawamoto Y, Kosai K, Ota K, Uno N, Sakamoto K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K: Rapid detection and surveillance of cfiA-positive *Bacteroides fragilis* using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Anaerobe* 72: 102448, 2021. (IF: 3.331) *
- 66 . Torigoe M, Kitamura M, Yamaguchi K, Uchino T, Torigoe K, Harada T, Funakoshi S, Yamamoto K, Maemura K, Eishi K, Mukae H, Nishino T: Association between serum phosphate levels and the development of aortic stenosis in patients undergoing hemodialysis. *J Clin Med* 10(19): 4385, 2021. (IF: 4.242) *
- 67 . Kaku N, Nishimura F, Shigeishi Y, Tachiki R, Sakai H, Sasaki D, Ota K, Sakamoto K, Kosai K, Hasegawa H, Izumikawa K, Ariyoshi K, Mukae H, Yasuda J, Morita K, Kohno S, Yanagihara K: Performance of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients: A retrospective study in outbreak on a cruise ship. *PLoS One* 16(9): e0257452, 2021. (IF: 3.240) *
- 68 . Ikegami H, Noguchi S, Fukuda K, Akata K, Yamasaki K, Kawanami T, Mukae H, Yatera K: Refinement of microbiota analysis of specimens from patients with respiratory infections using next-generation sequencing. *Sci Rep* 11(1): 19534, 2021. (IF: 4.380) *
- 69 . Fukushima K, Akagi K, Kondo A Kubo T, Ito Y, Oda Y, Nagihara Y, Sakamoto N, Mukae H: Evaluation of QFT-Plus assay performance using blood samples stored at room temperature. *Intl J Tuberc Lung Dis* 25(11): 948-949, 2021.
- 70 . Chojin Y, Kato T, Noguchi S, Rikihisa M, Omori M, Mukae H, Yatera K: Evaluating a novel swallowing assessment as a predictor of mortality and recurring pneumonia in elderly patients with pneumonia. *Respir Invest* 59(6): 783-791, 2021. (IF: 0.570) *
- 71 . Hisata S, Bando M, Homma S, Kataoka K, Ogure T, Izumi S, Sakamoto S, Watanabe K, Saito Y, Shimizu Y, Kato M, Nishioka Y, Hara H, Waseda Y, Tanino Y, Yatera K, Hashimoto S, Mukae H, Inase N: Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan. *Respir Investig* 59(6): 819-826, 2021. (IF: 0.570) *
- 72 . Shindo Y, Kondoh Y, Kada A, Doi Y, Tomii K, Mukae H, Murata N, Imai R, Okamoto M, Yamano Y, Miyazaki Y, Shinoda M, Aso H, Izumi S, Ishii H, Ito R, Saito AM, Saito T, Hasegawa Y: Phase II clinical trial of combination therapy with favipiravir and methylprednisolone for COVID-19 with non-critical respiratory failure. *Infect Dis Ther* 10(4): 2353-2369, 2021. (IF: 5.322) *
- 73 . Yoshimura A, Yamada T, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Nishiyama A, Yano S, Goto Y, Shiotsu S, Kunimasa K, Morimoto Y, Iwasaku M, Kaneko Y, Uchino J, Kenmotsu H, Takahashi T, Takayama K: Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. *Transl Lung Cancer Res* 10(8): 3582-3593, 2021. (IF: 6.498) *
- 74 . Yamaguchi K, Kitamura M, Takazono T, Sato S, Yamamoto K, Notomi S, Sawase K, Harada T, Funakoshi S, Mukae H, Nishino T: Association between the psoas muscle index and hospitalization for pneumonia in patients undergoing hemodialysis. *BMC Nephrol* 22(1): 394, 2021. (IF: 2.388) *
- 75 . Kitamura M, Takazono T, Yamaguchi K, Notomi S, Sawase K, Harada T, Funakoshi S, Mukae H, Nishino T: The impact of muscle mass loss and deteriorating physical function on prognosis in patients receiving hemodialysis. *Sci Rep* 11(1): 22290, 2021. (IF: 4.380) *
- 76 . Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM: Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. *J Hematol Oncol* 14(1): 170, 2021. (IF: 17.388) *
- 77 . Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Manoj P, Donoghue MTA, Won HH, Chan JM, Ciampricotti M, Chow A, Offin M, Chang JC, Ray-Kirton J, Tischfield SE, Egger JV, Bhanot UK, Linkov I, Asher M, Sinha S, Silber J, Iacobuzio-Donahue CA, Roehrl MH, Hollmann TJ, Yu HA, Qiu J, de Stanchina E, Baine MK, Rekhtman N, Poirier JT, Loomis B, Koche RP, Rudin CM, Sen T: Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. *Cancer Discov* 11 (12): 3028–3047, 2021. (IF: 39.397) *
- 78 . Kido T, Ishimoto H, Ishii H, Hara K, Ozasa M, Kawabata H, Kawanami T, Suzuki Y, Yoshikawa H, Hara A, Sakamoto N, Matsumoto N, Yoshii C, Fukuoka J, Fujita M, Nakazato M, Kadota J, Mukae H, Yatera K: Combined detection of lymphocyte clonality and MALT1 translocations in bronchoalveolar lavage fluid for diagnosing pulmonary lymphomas. *Sci Rep* 11(1): 23430, 2021. (IF: 4.380) *
- 79 . Akagi K, Fukushima K, Miyashita R, Kaneko Y, Ehara N, Kondo A, Kobo T, Mukae H: Tuberculosis pleural effusion diagnosed by negative control value of QUANTIFERON®: a prospective cohort study. *Kekkaku* 96(7): 191-194, 2021.
- 80 . Mukae H, Kaneko T, Obase Y, Shinkai M, Katsunuma T, Takeyama K, Terada J, Niimi A, Matsuse H, Yatera K, Yamamoto Y, Azuma A, Arakawa H, Iwanaga T, Ogawa H, Kurahashi K, Gon Y, Sakamoto H, Shibata Y, Tamada T, Nishioka Y, Haranaga S, Fujieda S, Miyashita N, Mochizuki H, Yokoyama A, Yoshihara S, Tamaoki J: JRS guidelines committee for the management of cough and sputum: The Japanese respiratory society guidelines for the management of cough and sputum (digest edition). *Respir Investig* 59(3): 270-290, 2021.

- 81 . Nakada-Motokawa N, Miyazaki T, Ueda T, Yamagishi Y, Yamada K, Kawamura H, Kakeya H, Mukae H, Mikamo H, Takesue Y, Kohno S: Modified pitt bacteremia score for predicting mortality in patients with candidemia: A multicentre seven-year retrospective study conducted in Japan. *Mycoses* 64(12): 1498-1507, 2021. (IF: 4.377) *
- 82 . Fukahori S, Obase Y, Fukushima C, Takao D, Iriki J, Ozasa M, Zaizen Y, Takamura N, Fukuoka J, Ashizawa K, Mukae H: Determining response to treatment for drug-Induced bronchocentric granulomatosis by the forced oscillation technique. *Medicina (Kaunas)* 57(12): 1315, 2021.
- 83 . Kitamura M, Yamaguchi K, Ota Y, Notomi S, Komine M, Etoh R, Harada T, Funakoshi S, Mukae H, Nishino T: Prognostic impact of polypharmacy by drug essentiality in patients on hemodialysis. *Sci Rep* 11 (1): 24238, 2021. (IF: 4.380) *
- 84 . Kaku N, Kodama H, Akamatsu N, Ota K, Kosai K, Morinaga Y, Narita Y, Matsumoto Y, Matsushita T, Mizuta Y, Izumikawa K, Mukae H, Yanagihara K: Multicenter evaluation of molecular point-of-care testing and digital immunoassays for influenza virus A/B and respiratory syncytial virus in patients with influenza-like illness. *J Infect Chemother* 27(6): 820-825, 2021. (IF: 2.211) *
- 85 . Shirahige T, Tashiro M, Taguchi M, Miyazaki Y, Shibuya K, Izumikawa K: Long-term trend in serum (1,3)-beta-D-glucan level in a man with chronic disseminated candidiasis treated with corticosteroids. *J Infect Chemother* 27(8): 1258-1260, 2021. (IF: 2.211) *
- 86 . Tanaka T, Mori M, Sekino M, Higashijima U, Takaki M, Yamashita Y, Kakiuchi S, Tashiro M, Morimoto K, Tasaki O, Izumikawa K: Impact of plasma 5-hydroxyindoleacetic acid, a serotonin metabolite, on clinical outcome in septic shock, and its effect on vascular permeability. *Sci Rep* 11(1): 14146, 2021. (IF: 4.380) *
- 87 . Tanaka T, Mori M, Tashiro M, Izumikawa K: Impact of plasma 5 hydroxyindoleacetic acid, a serotonin metabolite, on clinical severity in acute respiratory distress syndrome. *Front Med (Lausanne)* 8: 785409, 2021. (IF: 5.091)
- 88 . Tanaka T, Oshima K, Kawano K, Tashiro M, Tanaka A, Fujita A, Tsukamoto M, Yasuoka A, Teruya K, Izumikawa K: Nationwide surveillance of AIDS-defining illnesses among HIV patients in Japan from 1995 to 2017. *PLoS One* 16(8): e0256452, 2021. (IF: 3.240) *
- 89 . Muta K, Nakazawa Y, Obata Y, Inoue H, Torigoe K, Nakazawa M, Abe K, Furusu A, Miyazaki M, Yamamoto K, Koji T, Nishino T: An inhibitor of Kruppel-like factor 5 suppresses peritoneal fibrosis in mice *Perit Dial Int.* 41(4): 394-403, 2021.
- 90 . Morimoto M, Fujikawa K, Ide S, Akagi M, Fujiwara E, Mizokami A, Kawakami A: Systemic Lupus Erythematosus Complicated with *Listeria Monocytogenes* Infection in a Pregnant Woman. *Intern Med.* 2021 60(10):1627-1630. (IF: 1.271) *
- 91 . Kuwano K, Ota Y, Tsuji K, Torigoe K, Yamashita A, Muta K, Kitamura M, Yamashita H, Uramatsu T, Tashiro M, Hayashi H, Izumikawa K, Mukae H, Nishino T: An autopsy case of disseminated varicella zoster virus infection during the treatment of nephrotic syndrome. *Internal medicine* 61(4): 571-576, 2021. (IF: 1.282) *

A-b

- 1 . Yatera K, Noguchi S, Mukae H: Perspective on the clone library method for infectious diseases. *Respir Invest* 59(6): 741-747, 2021. (IF: 0.570)
- 2 . Hosogaya N, Takazono T, Miyazaki T, Furukawa M, Tanaka S, Kinoshita M, Mukae H: A protocol for randomized, controlled study of baloxavir marboxil compared with oseltamivir in patients with influenza virus infection aged 75 years and older. *Medicine* 2: 4, 2021. (IF: 1.889)

B 邦文

B-a

- 1 . 高園 貴弘、宮崎 泰可、吉田 祐樹、小嶋 悟史、細萱 直希、迎 寛: 75歳以上のインフルエンザ患者に対するバロキサビル マルボキシルの有効性, 安全性: CAPSTONE-2部分集団分. *感染症学雑誌* 95(1): 1-8, 2021
- 2 . 井上陽香、関野元裕、江頭 崇、矢野倫太郎、松本総次朗、東島 潮、松本周平、松丸一朗、江石清行、高園貴弘、迎 寛、原 哲也: 重篤な呼吸循環不全を来したが集中治療により早期手術を施行できた感染性心内膜炎の1例. *長崎医学会雑誌* 95(4): 273-278, 2021
- 3 . 三木 誠、三笠桂一、門田淳一、迎 寛、藤田次郎、柳原克紀、館田一博、戸塚恭一、梅本恭子、谷岡幸代子、河野 茂: 市中肺炎患者におけるlascufloxacin注射剤とlevofloxacin注射剤の第III相二重盲検比較試験. *日本化学療法学会雑誌* 69(3): 255-269, 2021
- 4 . 三木 誠、三笠桂一、門田淳一、迎 寛、藤田次郎、柳原克紀、館田一博、戸塚恭一、永楽智彦、河野 茂: 慢性呼吸器病変の二次感染、誤嚥性肺炎および肺膿瘍患者におけるlascufloxacin注射剤の一般臨床試験. *日本化学療法学会雑誌* 69(3): 270-285, 2021
- 5 . 小笹睦、澤井豊光、原田陽介、吉岡寿麻子、松尾信子、迎寛: 傍椎体腫瘍以外に病変を認めず肺腺癌を合併したIgG4関連疾患の1例. *肺癌第61巻 第3号*, 2021
- 6 . 巖水 慧、山本 和子、井手口周平、井手昇太郎、高園貴弘、高橋健介、赤松紀彦、泉川公一、柳原克紀、迎 寛. *Mycobacterium abscessus* による肺抗酸菌症の予後因子の検討. *日本呼吸器学会雑誌* 10(6) 1-8 2021.
- 7 . 海部佳純、石松祐二、松浦江美、神津玲、澤井照光、花田国利、原敦子、城戸貴志、石本裕士、坂本憲徳、尾長谷靖、田中宏典、迎寛. 間質性肺炎患者の身体活動量の特性と関連要因の検討. *保健学研究* 34: 67-75, 2021

B-b

- 1 . 迎 寛、山崎 啓、矢寺和博: 誤嚥性肺炎の起炎菌と抗生剤の使い方. *日本医師会雑誌* 149(12): 2149-2152, 2021
- 2 . 迎 寛: 市中肺炎の診断と治療. *日本内科学会雑誌* 110(3): 562-569, 2021
- 3 . 平山達朗、迎 寛: 肺炎 高齢者に多い疾患とその外来診療. *臨床と研究* 98(4), 427-432, 2021

4. 尾長谷靖、迎 寛:「咳嗽・喀痰の診療ガイドライン2019（日本呼吸器学会）」がもたらしたものと、次回改訂に向けた課題 特集・呼吸器疾患ガイドライン（改訂・発刊）がもたらしたものと、次回改訂に向けた課題.呼吸器内科 39(5): 395-400, 2021
5. 今村圭文、迎 寛:成人肺炎診療ガイドライン2017（日本呼吸器学会） 特集・呼吸器疾患ガイドライン（改訂・発刊）がもたらしたものと、次回改訂に向けた課題.呼吸器内科 39(5): 373-378, 2021
6. 岩永直樹、迎 寛: Withコロナ時代の肺炎診療.肺炎の治療-市中肺炎.臨床と研究. 98(11), 35-41, 2021.
7. 尾長谷靖、迎 寛: 慢性咳嗽の鑑別の進め方. Current Therapy 39（8）: 29-33, 2021
8. 迎 寛: 一般内科医が見落としたくない難治性感染症の診断と治療 3）肺アスペルギルス症. 日本内科学会雑誌 110(9): 1808-1814, 2021
9. 平山達朗、宮崎泰可: Withコロナ時代の肺炎診療.肺炎の治療-肺真菌症.臨床と研究. 98(11): 51-56, 2021
10. 平山達朗、宮崎泰可: COVID-19に合併する真菌感染症.呼吸器内科 40(4): 372-377, 2021.

B-c

1. 迎 寛: オウム病.今日の治療指針2021年版: 189-190, 2021
2. 高園貴弘、迎 寛: COVID-19の診断方法. COVID-19の病態・診断・治療: 62-68, 2021
3. 小笹睦、福岡順也.病理組織診断とPF-ILD.呼吸器内科Vol.39 No.3, 2021
4. 西條知見、迎 寛: 腎不全、透析患者の肺合併症.呼吸器疾患最新の治療2021-2022 351-354, 2021
5. 山本和子.第1章 肺炎の診断と治療、6.ワクチンによる肺炎予防.診断・治療から栄養管理・呼吸リハ・嚥下リハ・口腔ケアまで.誤嚥性肺炎の包括的アプローチ.医歯薬出版,東京,44-49.
6. 岩永直樹: Section 11 呼吸器. Chapter 48 胸水.フレームワークで考える内科診断.
7. メディカル・サイエンス・インターナショナル: 574-585. 2021.
8. 小笹睦、福岡順也. ATS/JRS/ALATガイドラインの病理診断.呼吸器内科Vol.40 No.2, 114-119, 2021
9. 高園貴弘: IX 呼吸器感染症 肺カンジダ症 .日本臨牀(別冊)「呼吸器症候群(第3版)IV」,180-181, 2021
10. 岩永直樹,迎 寛:I章 呼吸器感染症 4. 市中肺炎（非定型肺炎）.呼吸器内科学レビュー2022-23: 25-30. 2021
11. 福島千鶴、細萱直希、深堀 範、尾長谷靖、迎 寛: 熱帯性好酸球増多症.呼吸器症候群（第3版）II 181-184, 2021
12. 井手口周平、迎 寛: 生物学的製剤と感染症.標準的医療説明 インフォームド・コンセントの最前線 308-313, 2021
13. 城戸貴志、迎 寛: 肺胞出血.呼吸器症候群（第3版）III 145-149, 2021
14. 芦澤信之: 第2章 誤嚥性肺炎の診断と治療、2.誤嚥に関連するその他の肺疾患について.誤嚥性肺炎の包括的アプローチ 診断・治療から,栄養管理・呼吸リハ・嚥下リハ・口腔ケアまで.医歯薬出版株式会社: 59-65, 2021
15. 芦澤信之: 4.真菌感染症 (5)肺クリプトコックス症.呼吸器症候群（第3版）IV 182-186, 2021
16. 城戸貴志: 珪肺症.呼吸器症候群（第3版）III 205-209, 2021
17. 坂本憲徳: リンパ球性間質性肺炎.呼吸器症候群（第3版）III 108-111, 2021
18. 坂本憲徳: 外因性リポイド肺炎.呼吸器症候群（第3版）IV 315-317, 2021

B-e-1

1. 迎 寛: 誤嚥性肺炎 第17回 幸せに老いるためには. KYOREI 822(1): 26-27, 2021

論文研究業績集計表

論文数一覧

	A-a	A-b	A-c	A-d	A-e	合計	SCI	B-a	B-b	B-c	B-d	B-e	合計	総計
2021	91	2	0	0	0	93	77	7	10	18	0	1	36	129

学会発表数一覧

	A-a	A-b シンポジウム	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2021	0	1	6	7	2	31	96	129	136

論文総数に係る教員生産係数

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2021	0.721	5.471	0.828	4.529

Impact Factor 値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2021	406.018	23.883	5.273